90 related articles for article (PubMed ID: 31587751)
1. Regulation of serum uric acid with canagliflozin monotherapy in type 2 diabetes: A potential link between uric acid and pancreatic β-cell function
.
Kutoh E; Wada A; Kuto AN; Hayashi J
Int J Clin Pharmacol Ther; 2019 Dec; 57(12):590-595. PubMed ID: 31587751
[TBL] [Abstract][Full Text] [Related]
2. Two Glucose-Lowering Mechanisms of Canagliflozin Depending on Body Weight Changes in Drug-Naïve Subjects with Type 2 Diabetes.
Kutoh E; Wada A; Murayama T; Hayashi J
Drugs R D; 2018 Dec; 18(4):309-315. PubMed ID: 30324549
[TBL] [Abstract][Full Text] [Related]
3. Link between body weight changes and metabolic parameters in drugs naïve subjects with type 2 diabetes treated with canagliflozin monotherapy.
Kutoh E; Wada A; Kuto AN; Hayashi J; Kurihara R
Hosp Pract (1995); 2020 Mar; 48(2):68-74. PubMed ID: 32098545
[TBL] [Abstract][Full Text] [Related]
4. Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy.
Kutoh E; Wada A; Murayama T; Takizawa Y
Drugs R D; 2017 Jun; 17(2):313-320. PubMed ID: 28285448
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Adipose Tissue Insulin Resistance and Diabetic Parameters in Drug Naïve Subjects with Type 2 Diabetes Treated with Canagliflozin Monotherapy.
Kutoh E; Kuto AN; Ozawa E; Kurihara R; Akiyama M
Drug Res (Stuttg); 2023 Jun; 73(5):279-288. PubMed ID: 36882112
[TBL] [Abstract][Full Text] [Related]
6. Link between serum uric acid and pancreatic beta-cell function in drug naïve subjects with type 2 diabetes treated with sitagliptin.
Kutoh E; Wada A; Kuto AN; Hayashi J; Kurihara R
Hosp Pract (1995); 2021 Apr; 49(2):71-78. PubMed ID: 33191818
[No Abstract] [Full Text] [Related]
7. Regulations of Free Fatty Acids and Diabetic Parameters in Drug Naïve Subjects with Type 2 Diabetes Treated with Canagliflozin Monotherapy.
Kutoh E; Kuto AN; Wada A; Kurihara R; Kojima R
Drug Res (Stuttg); 2022 Feb; 72(2):86-93. PubMed ID: 34729722
[TBL] [Abstract][Full Text] [Related]
8. [Serum Uric Acid and Islet β-cell Function in Patients with Pre-diabetes and Type 2 Diabetes Mellitus].
Wu YT; He H; Wang X; Zhang M; An ZM; Huang HJ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 49(1):69-73. PubMed ID: 29737093
[TBL] [Abstract][Full Text] [Related]
9. Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.
Kutoh E; Murayama T; Wada A; Hirate M
Drugs R D; 2016 Dec; 16(4):369-376. PubMed ID: 27798769
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Metabolic Parameters in Responders and Nonresponders Treated with Canagliflozin Monotherapy in Drug-naive Subjects with Type 2 Diabetes.
Kutoh E; Wada A; Murayama T; Hayashi J
Indian J Endocrinol Metab; 2018; 22(2):185-190. PubMed ID: 29911028
[TBL] [Abstract][Full Text] [Related]
11. REGULATION OF FREE FATTY ACID BY SITAGLIPTIN MONOTHERAPY IN DRUG-NAÏVE SUBJECTS WITH TYPE 2 DIABETES.
Kutoh E; Wada A; Hayashi J
Endocr Pract; 2018 Dec; 24(12):1063-1072. PubMed ID: 30289315
[TBL] [Abstract][Full Text] [Related]
12. Serum uric acid to creatinine ratio correlates with β-cell function in type 2 diabetes.
Li M; Gu L; Yang J; Lou Q
Diabetes Metab Res Rev; 2018 Jul; 34(5):e3001. PubMed ID: 29504280
[TBL] [Abstract][Full Text] [Related]
13. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.
Davies MJ; Trujillo A; Vijapurkar U; Damaraju CV; Meininger G
Diabetes Obes Metab; 2015 Apr; 17(4):426-9. PubMed ID: 25600248
[TBL] [Abstract][Full Text] [Related]
14. Complementary effects on glycaemic and non-glycaemic parameters between responders and non-responders treated with pioglitazone and canagliflozin in drug-naive subjects with type 2 diabetes.
Kutoh E; Kuto AN; Wada A; Kurihara R; Kojima R
Int J Clin Pract; 2021 Dec; 75(12):e14914. PubMed ID: 34551185
[TBL] [Abstract][Full Text] [Related]
15. Effect of Pioglitazone on Serum Uric Acid Levels in Newly Diagnosed, Drug-Naïve Patients with Type 2 Diabetes.
Kutoh E; Hori T
Endocr Res; 2013 Aug; 38(3):151-159. PubMed ID: 23216460
[TBL] [Abstract][Full Text] [Related]
16. Serum uric acid change and modification of blood pressure and fasting plasma glucose in an overall healthy population sample: data from the Brisighella heart study.
Cicero AF; Rosticci M; Bove M; Fogacci F; Giovannini M; Urso R; D'Addato S; Borghi C;
Ann Med; 2017 Jun; 49(4):275-282. PubMed ID: 27499431
[TBL] [Abstract][Full Text] [Related]
17. The relationship between serum uric acid within the normal range and β-cell function in Chinese patients with type 2 diabetes: differences by body mass index and gender.
Zhong X; Zhang D; Yang L; Du Y; Pan T
PeerJ; 2019; 7():e6666. PubMed ID: 30941277
[TBL] [Abstract][Full Text] [Related]
18. Correlation between serum uric acid and diabetic peripheral neuropathy in T2DM patients.
Lin X; Xu L; Zhao D; Luo Z; Pan S
J Neurol Sci; 2018 Feb; 385():78-82. PubMed ID: 29406919
[TBL] [Abstract][Full Text] [Related]
19. Serum uric acid concentration is associated with worsening in severity of diabetic retinopathy among type 2 diabetic patients in Taiwan--a 3-year prospective study.
Lee JJ; Yang IH; Kuo HK; Chung MS; Chen YJ; Chen CH; Liu RT
Diabetes Res Clin Pract; 2014 Nov; 106(2):366-72. PubMed ID: 25108898
[TBL] [Abstract][Full Text] [Related]
20. Impact of diabetes on uric acid and its relationship with the extent of coronary artery disease and platelet aggregation: a single-centre cohort study.
Verdoia M; Barbieri L; Schaffer A; Cassetti E; Nardin M; Bellomo G; Aimaretti G; Marino P; Sinigaglia F; De Luca G;
Metabolism; 2014 May; 63(5):640-6. PubMed ID: 24606806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
